UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas
Cancer Letters · 2026-12 · 662 · 218905
DOI: 10.1016/j.canlet.2026.218905 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Zhonglan Dong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Department of Cancer Neuroscience, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research C…. Hauptthemen laut MEDLINE: DNA Polymerase II, Esophageal Squamous Cell Carcinoma, Ubiquitins, Carcinoma, Squamous Cell. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
While immune checkpoint inhibitors (ICIs) have revolutionized treatment of the patients with aero-upper digestive squamous cell carcinomas (SCCs), including esophageal squamous cell carcinoma (ESCC) and lung squamous cell carcinoma (LUSC), only a subset of patients benefit from ICIs, therefore entailing exploration of the mechanisms to regulate treatment responsiveness. POLE, as a subunit of DNA polymerase ε, possesses 3'-5' proofreading activity, and its mutations have been associated with favourable response to ICIs in several solid tumors. However, post-translational modification (PTM) of POLE and its impact on the therapeutic efficacy of ICIs are unknown. Here, this study demonstrates that ubiquitin-like protein 3 (Ubl3), whose expression is markedly downregulated in SCCs, covalently binds to Pole, reduces nuclear Pole levels, triggers DNA damage, and activates cGAS-STING signaling pathway. Notably, Ubl3 modification of Pole significantly primes the local immune microenvironment to mitigate the growth of murine aero-upper digestive SCC cells and boost the efficacy of αPD-1 treatment in vivo. Single-cell RNA sequencing (scRNA-seq) analysis further revealed that UBL3 expression is positively correlated with better clinical outcomes in a cohort of ESCC patients receiving neoadjuvant chemotherapy combined with αPD-1. Together, our findings unravel UBL3 modification as a novel PTM mechanism governing subcellular location of POLE and its influence on immunotherapy responsiveness, thus making UBL3 modification as a promising immunomodulatory approach to enhance immunotherapy efficacy in patients with aero-upper digestive SCCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Department of Cancer Neuroscience, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China; Tianjin Key Laboratory of…
- Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China; Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060…
- Burning Rock Biotech, Guangzhou, 510300, PR China. Electronic address: lei.zhang@brbiotech.com.
- Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China; Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, PR C…
- Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China; Tianjin Key Laboratory of…
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, PR…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Dong, Z., Huang, W., Zhang, L., Guo, Q., Zhang, X., Yang, Y., Wang, X., Liu, Z., Yin, Y., & Ma, G. (2026). UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas. Cancer Letters, 662, 218905. https://doi.org/10.1016/j.canlet.2026.218905
Vancouver
Dong Z, Huang W, Zhang L, Guo Q, Zhang X, Yang Y, et al. UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas. Cancer Letters. 2026;662:218905. doi:10.1016/j.canlet.2026.218905
BibTeX
@article{Dong2026,
author = {Dong, Zhonglan and Huang, Wenbai and Zhang, Lei and Guo, Qianru and Zhang, Xiaobei and Yang, Yang and Wang, Xudong and Liu, Zhihua and Yin, Yiqing and Ma, Gang},
title = {UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas},
journal = {Cancer Letters},
year = {2026},
volume = {662},
pages = {218905},
doi = {10.1016/j.canlet.2026.218905}
}
EUVIMED